Drug updated on 4/17/2024
| Dosage Form | Injection (intravenous; 240 mg/6 mL [40 mg/mL] solution in a single-dose vial) |
| Drug Class | Programmed death receptor-1 (PD-1) blocking antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated, in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC).
- Indicated as single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.
Summary
- Toripalimab-tpzi (Loqtorzi) is recommended for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), in combination with cisplatin and gemcitabine. It is also utilized as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC who have disease progression on or after platinum-containing chemotherapy.
- The study compared different immune checkpoint inhibitors combined with chemotherapy as first-line treatments for recurrent or metastatic NPC.
- In terms of efficacy, Toripalimab plus gemcitabine-cisplatin demonstrated a significant improvement in overall survival over placebo plus GP, indicating better outcomes for individuals treated with this combination. Nonetheless, Tislelizumab provided the best Progression-Free Survival benefit and objective response rate compared to placebo plus GP.
- Despite its effectiveness in improving overall survival rates among individuals with NPC, Toripalimab has been associated with more safety concerns than Tislelizumab, considering adverse events of grade ≥3, treatment-related adverse events of grade ≥3, serious adverse events (SAEs), treatment-related SAEs, and discontinuations due to these effects.
- While both drugs are effective in treating NPCs according to their indications, considerations including previous treatments and specific patient subgroups need to be taken into account during personalized planning, as these factors may influence the choice between Toripalimab and Tislelizumab based on their balance of efficacy and safety profiles respectively.
- Toripalimab might be deemed a preferable option for some due to its promising efficacy, despite the considerations regarding its safety profile.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Loqtorzi (toripalimab-tpzi) Prescribing Information | 2023 | Coherus BioSciences |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a network meta-analysis of randomized controlled trials. | 2023 | The Annals of Pharmacotherapy |